Fractionated administration of gemtuzumab ozogamicin for refractory acute myeloid leukemia.
It is difficult to decide an appropriate treatment strategy for elderly leukemia patients with other complications. We encountered 2 cases of refractory acute myeloid leukemia and safely treated the patients with fractionated administration of gemtuzumab ozogamicin (GO). Standard induction therapies were not effective for these patients. Moreover, they suffered from complications due to which their treatment options were restricted. Fractionated administration of GO (GO 3 mg/m(2) on days 1, 3 and 5) was accomplished safely and alleviated the patients' conditions. After treatment, these patients were followed by outpatient basis. We consider that this is an impressive treatment because fractionated administration of GO is potentially less toxic. Further, it will be helpful to maintain or improve the QOL of patients who are unable to receive intensive chemotherapy. These cases were significant because fractionated GO treatment is potentially less toxic and it will be helpful to maintain or improve the QOL of patients who can not receive intensive chemotherapy.
YAHAGI
Yuichi
Y
Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine.
USUI
Noriko
N
YAMAGUCHI
Yuko
Y
DOBASHI
Nobuaki
N
YANO
Shingo
S
TAKEI
Yutaka
Y
SUGIYAMA
Katsuki
K
TAKAHARA
Shinobu
S
SAITO
Takeshi
T
MINAMI
Jiro
J
KOBAYASHI
Tatsunosuke
T
KAMIYAMA
Yutaro
Y
MORIKAWA
Tetsuyuki
T
AIBA
Keisuke
K
D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D016896:Treatment Outcome
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000079982:Gemtuzumab